hematologic malignacy
Conditions
Interventions
Group 1:oral dasatanib
Group 2:oral sorafenib
Group 3:oral placebo
Sponsors
the First Affiliated Hospital of Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
No minimum to 60 Years
Inclusion criteria
Inclusion criteria: 1. The informed consent is signed by the subjects or their legal representatives before the start of clinical research; 2. Male and female patients,and the female patients with negative pregnancy test; 3. aged younger than 60 years old; 4. Patients diagnosed with acute myeloid leukemia with t(8;21)(q22;q22.1)or inv(16)(p13.1q22) or t(16;16)(p13.1;q22) [inv(16)and t(16;16)] who undergo allogeneic hematopoietic stem cell transplantation; 5. ECOG physical status score 0~2 score; 6. No major organ dysfunction.
Exclusion criteria
Exclusion criteria: 1. Patients with severe liver and renal function and heart and lung dysfunction; 2. An uncontrolled or severe infection; 3. Poor implantation after transplantation or blood routine examination is not satisfied with WBC>2.0*10^9/L, ANC>0.5*10^9/L, HBG>90g/L, PLT>20*10^9/L. 4.ECOG performance status >2; 5. second tumour; 6. severe neurologic and psychiatric disorder interfering with the ability to consent on the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival;disease-free survival;cumulative replase rate;nonreplase mortality;the incidence of acute GVHD and chronic GVHD;Adverse Effects Rate;infection rate; | — |
Countries
China
Contacts
Public ContactHuang He
the First Affiliated Hospital of Zhejiang University School of Medicine
Outcome results
None listed